 |
Platform technologiesThe increase in MAb purification productivity has created a demand on processes downstream to provide enhanced capacity and speed. In addition, since only a small proportion of biotherapeutics that enter clinical trials make it to market, companies tend to populate the candidate pipeline, meaning more processes require development in shorter timeframes. The solution is represented by the MAb platform approach.
The MAb Production Scheme is designed to give you an overview of the different unit operations suggested in the MAb platform of GE Healthcare. In addition, each unit operation includes suggestions of state of the art product solutions, designed to meet the latest demands of the production of a biopharmaceutical.
Explore MAb Production Scheme
Platform technologies facilitate rapid and economical process development and scale-up, potentially allowing evaluation of a larger number of product candidates, speeding market entry and even reducing the validation effort. Platform technologies are composed of a number of unit operations and methods and not just purification steps. Platform technologies can also reduce validation costs.
Read more about MAb purification challenge.
|
